# US 2004/0204374 A1 · Cis-element decoys useful as anti-tumor therapeutics

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0204374 A1
- Document ID: US20040204374A1
- Status: Published application
- Kind: A1
- Application number: 10/411,692
- Filed: 2003-04-11
- Published: 2004-10-14
- Earliest claimed: 2003-04-11
- Inventors: Xuegen Wang; Qing Ye; Wuling Chen; Ying Feng
- Web page: https://patentgrep.com/patent/US20040204374A1

## CPC

- C07H 21/04: with deoxyribosyl as saccharide radical
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

An anti-cancer or oncogene switching therapeutics that employ sequence-specific nucleic acid decoys for competitive binding of transcription factors. These nucleic acid decoys can competitively bind to transcription factors regulating the expression of oncogenes including CREB, JUN/FOS, JUN/ATF and MYC/MAX in the cell, leading to the inhibition of tumor cell growth. As a result, they can be developed into anti-cancer therapeutic drugs.

## Claims

### Claim 1

An isolated composition comprising a 15-45 oligonucleotide sequence having a double-stranded structure having affinity for binding a transcription factor in a host cell.

### Claim 2 (depends on 1)

The composition, as recited in claim 1, wherein said polynucleotide sequence is selected from a group consisting of SEQ ID NO: 1 to 30.

### Claim 3 (depends on 1)

The composition, as recited in claim 1, wherein said transcription factor is selected from a group consisting of CREB, AP1(JUN/FOS), JUN/ATF, C-MYC and MYC/MAX.

### Claim 4 (depends on 1)

The composition, as recited in claim 1, wherein said host cell is a mammalian cell.

### Claim 5 (depends on 4)

The composition, as recited in claim 4, wherein said mammalian cell is a human cell.

### Claim 6 (depends on 5)

The composition, as recited in claim 5, wherein said human cell is a human cancer cell.

### Claim 7 (depends on 1)

The composition, as recited in claim 1, wherein said polynucleotide is double-stranded.

### Claim 8 (depends on 1)

The composition, as recited in claim 1, wherein said polynucleotide has a single-stranded structure which is able to form said double-stranded structure through an intra-chain interaction.

### Claim 9 (depends on 1)

The composition, as recited in claim 1, wherein said polynucleotide has a single-stranded structure which is able to form said double-stranded structure through an inter-chain interaction.

### Claim 10 (depends on 1)

The composition, as recited in claim 1, wherein said polynucleotide has a single-stranded structure which is able to, through an intra-chain interaction, form a secondary structure selectively comprising hairpin, pseudo-knot, stem and loop, dumb-bell and cruciform.

### Claim 11 (depends on 1)

The composition, as recited in claim 1, wherein said polynucleotide has a single-stranded structure which is able to, through an inter-chain interaction, form a secondary structures selectively comprising hairpin, pseudo-knot, stem and loop, dumb-bell and cruciform.

### Claim 12 (depends on 1)

The composition, as recited in claim 1, wherein said polynucleotide comprises a nucleotide analog.

### Claim 13 (depends on 12)

The composition, as recited in claim 12, wherein said nucleotide analog is selected from a group consisting of deoxyuracil, labeled nucleotide, ribonucleotide, 7-deaza-dNTP, methylthio-linked nucleotide, phosphothio-linked nucleotide, morpholino nucleotide, hexose-containing nucleotide, peptide nucleic acid (PNA) and derivatives thereof.

### Claim 14 (depends on 12)

The composition, as recited in claim 12, wherein said nucleotide analog is labeled and attached with a ligand molecule selected from a group consisting of lipophilic substrate, target-specific antibodies or other molecules with targeting functions and a combination thereof.

### Claim 15 (depends on 1)

The composition, as recited in claim 1, wherein said polynucleotide is formulated into pharmaceutical formulation selected from a group consisting of injectable, oral, transdermal, bolus, aerosol, suppository, transfectional and transgenic formulations and a combination thereof.

### Claim 16

An isolated composition comprising a 15-45 oligonucleotide comprising a double-stranded sequence 5′-STGACGTMR-3′ which is capable of binding to transcription factor CREB.

### Claim 17

An isolated composition comprising a 15-45 oligonucleotide comprising a double-stranded sequence 5′-STGASTMA-3′ which is capable of binding to transcription factor AP-1 (JUN/FOS).

### Claim 18

An isolated composition comprising a 15-45 oligonucleotide comprising a double-stranded sequence 5′-TTACCTCA-3′ which is capable of binding to transcription factor JUN/ATF.

### Claim 19

An isolated composition comprising a 15-45 oligonucleotide comprising a double-stranded sequence 5′-TCTCTTA-3′ which is capable of binding to transcription factor C-MYC.

### Claim 20

An isolated composition comprising a 15-45 oligonucleotide comprising a double-stranded sequence 5′-RACCACGTGGTY-3′ which is capable of binding to transcription factor MYC/MAX.

### Claim 21

An isolated composition comprising an element selected from a group consisting of (a) a polynucleotide selected from a group consisting of a 15-45 oligonucleotide comprising a double-stranded sequence 5′-STGACGTMR-3′ which is capable of binding to transcription factor CREB, a 15-45 oligonucleotide comprising a double-stranded sequence 5′-STGASTMA-3′ which is capable of binding to transcription factor AP-1 (JUN/FOS), a 15-45 oligonucleotide comprising a double-stranded sequence 5′-TTACCTCA-3′ which is capable of binding to transcription factor JUN/ATF, a 15-45 oligonucleotide comprising a double-stranded sequence 5′-TCTCTTA-3′ which is capable of binding to transcription factor C-MYC, and a 15-45 oligonucleotide comprising a double-stranded sequence 5′-RACCACGTGGTY-3′ which is capable of binding to transcription factor MYC/MAX; (b) a polynucleotide of at least 70% homology to the polynucleotide of (a); and (c) a combination thereof.

### Claim 22 (depends on 21)

The composition, as recited in claim 21, wherein said polynucleotide is double-stranded.

### Claim 23 (depends on 21)

The composition, as recited in claim 21, wherein said polynucleotide has a single-stranded structure which is able to form said double-stranded structure through an intra-chain interaction.

### Claim 24 (depends on 21)

The composition, as recited in claim 21, wherein said polynucleotide has a single-stranded structure which is able to form said double-stranded structure through an inter-chain interaction.

### Claim 25 (depends on 21)

The composition, as recited in claim 21, wherein said polynucleotide has a single-stranded structure which is able to, through an intra-chain interaction, form a secondary structure selectively comprising hairpin, pseudo-knot, stem and loop, dumb-bell and cruciform.

### Claim 26 (depends on 21)

The composition, as recited in claim 21, wherein said polynucleotide has a single-stranded structure which is able to, through an inter-chain interaction, form a secondary structure selectively comprising hairpin, pseudo-knot, stem and loop, dumb-bell and cruciform.

### Claim 27 (depends on 21)

The composition, as recited in claim 21, wherein said polynucleotide comprising a nucleotide analog.

### Claim 28 (depends on 27)

The composition, as recited in claim 27, wherein said nucleotide analog is selected from a group consisting of deoxyuracil, labeled nucleotide, ribonucleotide, 7-deaza-dNTP, methylthio-linked nucleotide, phosphoramidite, phosphothio-linked nucleotide, morpholino nucleotide, hexose-containing nucleotide, peptide nucleic acid (PNA) and derivatives thereof.

### Claim 29 (depends on 28)

The composition, as recited in claim 28, wherein said nucleotide analog is labeled and attached with a ligand molecule selected from a group consisting of lipophilic substrate, target-specific antibodies or other molecules with targeting functions and a combination thereof.

### Claim 30 (depends on 21)

The composition, as recited in claim 21, wherein said polynucleotide is formulated into pharmaceutical formulation selected from a groups consisting of injectable, oral, transdermal, bolus, aerosol, suppository, transfectional and transgenic formulations and a combination thereof.

### Claim 31

A method for regulating gene transcription and cell growth in a target cell comprising the steps of:
a) providing one or more transcription regulatory element decoys each comprising a polynucleotide, wherein said polynucleotide is selected from a group consisting of SEQ ID NO: 1 to 30; and
b) exposing said target cell to said polynucleotide under a condition that said polynucleotide alters gene transcription and cell growth.

### Claim 32 (depends on 31)

The method, as recited in claim 31, wherein the said target cell is a human cancer cell.

### Claim 33 (depends on 31)

The method, as recited in claim 31, wherein said target cell is exposed to said polynucleotide by injection.

### Claim 34 (depends on 31)

The method, as recited in claim 31, wherein said target cell is exposed to said polynucleotide by direct exposure.

### Claim 35 (depends on 31)

The method, as recited in claim 31, wherein said target cell is exposed to said polynucleotide by oral intake.

### Claim 36 (depends on 31)

The method, as recited in claim 31, wherein said target cell is exposed to said polynucleotide by transfection.

### Claim 37 (depends on 31)

The method, as recited in claim 31, wherein said target cell is exposed to said polynucleotide by transgenic expression.
